HORIZON FVF3426g

Research Title: An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

Sponsor: Genentech

Principal Investigator: Jay Stallman, M.D.

Description: This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in subjects with primary or recurrent CNV secondary to AMD who have completed the treatment phase of a Genentech sponsored study (FVF2598g, FVF2587g, or FVF2428g) or subjects with macular edema secondary to RVO who have completed the 6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored study (FVF4165g or FVF4166g). The study will enroll two subsets of subjects: ranibizumab experienced and ranibizumab-naive. Subjects should be enrolled within 14 days of completion of the 24-month treatment phase of the previous study.

Start Date: September 2006

Recruitment: Completed

Project Personnel: Leslie Marcus, CCRC

Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084